Arcellx Inc (ACLX) - News Archive

Arcellx Inc. (NASDAQ: ACLX) has announced promising new data from its iMMagine-1 study, which evaluates the efficacy of its innovative therapies for patients with relapsed or refractory multiple myeloma. This significan...

In a rapidly evolving landscape of cancer therapeutics, cell therapies are heralding a new era of hope for patients battling difficult-to-treat malignancies. Among the promising developments in this domain is Arcellx s...

Arcellx Reports Promising Q2 2024 Results, Highlighting Advancements in Innovative Cell Therapies REDWOOD CITY, Calif. Arcellx, Inc. (NASDAQ: ACLX), a biotechnology leader recognized for its groundbreaking approaches to...

Arcellx Inc. (NASDAQ: ACLX), based in Redwood City, California, and Kite, a Gilead Company (NASDAQ: GILD), based in Santa Monica, California, have announced their operational updates today on their jointly developed ani...

Arcellx and Kite, a Gilead Company, recently provided updates on their anitocabtagene autoleucel (anito-cel) multiple myeloma program, showcasing significant progress in its development. The collaboration between the tw...